Skip to main content

Table 1 Patient characteristics

From: In vivo efficacy of endothelial growth medium stimulated mesenchymal stem cells derived from patients with critical limb ischemia

 

1

2

3

4

5

6

7

Patients characteristics

 Age (years)

74

57

52

57

74

62

42

 Gender (M: male; F: female)

M

M

M

M

F

M

M

 BMI (kg/m2)

27

25

26

32

20

22

21

 Smoker

No

Past

Past

Past

No

Past

Current

 Arterial hypertension

Yes

Yes

No

No

No

Yes

No

 Hyperlipidemia

Yes

No

Yes

No

Yes

No

No

 Diabetes mellitus

Yes

No

Yes

No

No

No

No

 Disease characteristics

  TcPO2 (mmHg)

26

30

64

35

45

1

7

  Presence of ulcers

No

No

Yes

No

No

No

No

 Cardioprotective drugs usea

AT, ACEI

AT, ACEI, S

AT, ACEI, S

AT, ACEI, S

AT

AT, S

AT, S

BMC characterization

 PLTs (G/L)

746

740

478

590

384

1296

1118

 Total nucleated cells (G/L):

47

60

38

48

50

76

71

 Total MNCs

  Lymphocytes (%)

46

47

39

41

48

46

54

  Monocytes (%)

18

12

28

18

19

14

13

  Erythroblasts and other cells (%)b

10.5

14.3

10.4

19.8

12.7

13.2

14.5

 Mature granulocytes (%)

23

23

18

16

17

23

16

 HSCs (CD34+ cells) (%)

2.5

3.7

4.6

5.2

3.3

3.8

2.5

 MSCsc

42

38

34

58

28

12

60

Placebo or BMCs group

BMCs

BMCs

Placebo

Placebo

BMCs

BMCs

Placebo

Clinical outcome at 6 months

∅

∅

∅

∅

∅

Revascularization at day 126

Major amputation at day 114

Clinical outcome at 12 months

Revascularization at day 332

∅

∅

∅

∅

  
  1. Quantitative variables are expressed as median or absolute value. Biologic markers measured in 7 NO-CLI patients on day 0 (baseline) before CT
  2. ∅: Patient alive without any major amputation
  3. aCardioprotective drugs use: antiplatelet therapy (AT), statins (S), angiotensin-converting enzyme inhibitor (ACEI)
  4. bOther cells: blasts, immature granulocytes and plasma cells
  5. cCFU-F number/1 Ã— 106 nucleated cells